Technical Analysis for PULM - Pulmatrix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -2.98% | |
New 52 Week Low | Weakness | -2.98% | |
Outside Day | Range Expansion | -2.98% | |
Gapped Up | Strength | -2.98% |
Alert | Time |
---|---|
Possible Inside Day | about 9 hours ago |
60 Minute Opening Range Breakdown | about 12 hours ago |
Down 5% | about 12 hours ago |
Down 3% | about 12 hours ago |
Fell Below Lower Bollinger Band | about 12 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/28/2024
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Cystic Fibrosis Pulmonary Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Clinical Development Rare Diseases Chronic Obstructive Pulmonary Disease Cystic Fibrosis Pulmonary Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.185 |
52 Week Low | 1.57 |
Average Volume | 15,602 |
200-Day Moving Average | 2.16 |
50-Day Moving Average | 1.85 |
20-Day Moving Average | 1.86 |
10-Day Moving Average | 1.81 |
Average True Range | 0.14 |
RSI (14) | 34.21 |
ADX | 20.02 |
+DI | 13.55 |
-DI | 24.01 |
Chandelier Exit (Long, 3 ATRs) | 1.62 |
Chandelier Exit (Short, 3 ATRs) | 2.00 |
Upper Bollinger Bands | 2.09 |
Lower Bollinger Band | 1.64 |
Percent B (%b) | -0.01 |
BandWidth | 24.17 |
MACD Line | -0.04 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0323 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.84 | ||||
Resistance 3 (R3) | 1.85 | 1.79 | 1.81 | ||
Resistance 2 (R2) | 1.79 | 1.74 | 1.79 | 1.79 | |
Resistance 1 (R1) | 1.71 | 1.70 | 1.68 | 1.70 | 1.78 |
Pivot Point | 1.65 | 1.65 | 1.64 | 1.65 | 1.65 |
Support 1 (S1) | 1.57 | 1.60 | 1.54 | 1.56 | 1.48 |
Support 2 (S2) | 1.51 | 1.56 | 1.51 | 1.47 | |
Support 3 (S3) | 1.43 | 1.51 | 1.46 | ||
Support 4 (S4) | 1.42 |